Nabla Bio
We use AI to design antibodies for intractable diseases
About Nabla Bio
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
Company details
Funding
Total raised
$107.3M
Last stage
Series C
Investors
Founders
Frances Anastassacos
Currently building Nabla Bio! I've spent the last 8 years applying my chemistry training to problems in biology and specifically synthetic biology. I did my PhD at Harvard (Class 2019, BBS) and spent some time in biotech VC.
George Church
Renowned Harvard geneticist; Surge Biswas' doctoral advisor at Harvard.
Surge Biswas
Scientist with 10+ years of experience in synthetic biology and machine learning; completed PhD from George Church's lab at Harvard; pioneered protein language models published in Nature Methods and Nature Biotechnology.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.